GLP-1 Receptor Agonist As Adjuvant Therapy in Type 1 Diabetes: No Apparent Benefit for Beta-Cell Function or Glycemia

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2020 Jun 3

PMID 32485735

Citations 4

Authors

Maria J Redondo

Fida Bacha

Affiliations

Soon will be listed here.

Citing Articles

Advances in clinical research on glucagon.

Horie I, Abiru N Diabetol Int. 2024; 15(3):353-361.

PMID: 39101175 PMC: 11291794. DOI: 10.1007/s13340-024-00705-w.

Pancreatic beta-cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes.

Moon J, Choe H, Lim S J Diabetes Investig. 2024; 15(6):669-683.

PMID: 38676410 PMC: 11143426. DOI: 10.1111/jdi.14221.

Semaglutide Treatment in Adult-Onset Autoimmune Diabetes: A Case Study With Long-Term Follow-Up and Periodic Evaluation of Beta-Cell Function.

Da Porto A, Varisco E, Antonello M, Casarsa V, Sechi L Cureus. 2024; 16(3):e55771.

PMID: 38586652 PMC: 10999013. DOI: 10.7759/cureus.55771.

Diabetes of Unclear Type in an Adolescent Boy With Multiple Islet-cell Autoantibody Positivity Successfully Managed With Glucagon-like Peptide-1 Receptor Agonist Alone: A Case Report.

Ginnard O, Redondo M, Lyons S Can J Diabetes. 2022; 47(1):90-93.

PMID: 36075851 PMC: 10024250. DOI: 10.1016/j.jcjd.2022.07.006.

References

Johansen N, Dejgaard T, Lund A, Schluntz C, Frandsen C, Forman J . Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2020; 8(4):313-324. DOI: 10.1016/S2213-8587(20)30030-9. View

Pozzilli P, Bosi E, Cirkel D, Harris J, Leech N, Tinahones F . Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes. J Clin Endocrinol Metab. 2020; 105(6). DOI: 10.1210/clinem/dgaa149. View

Aronson R, Gottlieb P, Christiansen J, Donner T, Bosi E, Bode B . Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care. 2014; 37(10):2746-54. PMC: 4392937. DOI: 10.2337/dc13-0327. View

Andersen A, Lund A, Knop F, Vilsboll T . Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018; 14(7):390-403. DOI: 10.1038/s41574-018-0016-2. View

Dejgaard T, Frandsen C, Hansen T, Almdal T, Urhammer S, Pedersen-Bjergaard U . Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015; 4(3):221-232. DOI: 10.1016/S2213-8587(15)00436-2. View